<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03048032</url>
  </required_header>
  <id_info>
    <org_study_id>MIP-049/2015</org_study_id>
    <secondary_id>MIP-049/2015</secondary_id>
    <secondary_id>L-15-01/1</secondary_id>
    <nct_id>NCT03048032</nct_id>
  </id_info>
  <brief_title>Lithuanian Echocardiography Study of Dyspnea in Acute Settings</brief_title>
  <acronym>LEDA</acronym>
  <official_title>Diagnostic and Prognostic Value of Cardiac Biomarkers and Echocardiography for Patients Hospitalized Due to Acute Dyspnea: Prospective Observational Multicenter Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vilnius University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lithuanian University of Health Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vilnius University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      LEDA (Lithuanian Echocardiography study of Dyspnea in Acute settings) is a prospective
      observational cohort multicenter clinical study. Project is carried out by Vilnius University
      together with a partner Lithuanian University of Health Sciences, in conjunction with a
      research protocol of international GREAT consortium (Global Research on Acute Conditions
      Team). The aim of this project is to find the specific novel biomarkers of acute heart
      failure (AHF), to evaluate their diagnostic and prognostic role in association with
      echocardiographic parameters of AHF. Primary endpoint is 1-year all-cause mortality and
      rehospitalization. Secondary endpoints are 1) in-hospital all-cause mortality 2)
      post-discharge 1 and 3 month all-cause mortality and rehospitalization 3) post-discharge 1
      and 3 month cardiovascular mortality and rehospitalization 4) one-year cardiovascular
      mortality and rehospitalization.

      During the project a sizeable national database (2000 Lithuanian patients) will be integrated
      into database of GREAT network. Novel cardiac biomarkers together with ultrasound parameters
      of right ventricular (RV) function are in the focus of the study. During the acute phase of
      heart failure, up to 15 novel cardiac, vascular, renal impairment and inflammation biomarkers
      in plasma samples will be investigated in Lithuania and France (INSERM laboratory). Plasma
      samples will be taken during 4 hours after admission and frozen at -80ºC to allow batch
      analysis. The extensive evaluation of innovative ultrasound parameters of right ventricular
      structure and function will be performed in the early hospitalization period, along with
      standard echocardiography examination. The first database of AHF patients in Lithuania will
      provide demographic data and trends of morbidity and mortality, as well as analysis of
      diagnostic and prognostic value of novel biomarkers and echocardiography parameters in the
      Baltic region. Quantitative parameters of RV systolic function and deformation will be
      measured. It is expected that optimal use of novel biomarkers and reproducible
      echocardiography parameters in the setting of emergency and critical care would reduce
      unnecessary hospitalizations, cost and hospital length of stay without decrease in the
      quality of diagnostics and treatment. An estimation of correlation of echocardiographic
      parameters and biomarkers could help create an accurate algorithm for risk stratification and
      diagnosis of AHF in an emergency setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Heart failure (HF) is believed to be the modern-day epidemic due to increasing incidence,
      impaired long-term prognosis and huge economic burden. With the ageing population the impact
      of HF on health care resources is on the rise. The course of the disease is characterized by
      episodes of acute decompensation that mark a significant turning point in the progress of the
      disease, with in-hospital mortality rates as high as 10%. Acute heart failure (AHF) is a
      gradual or rapid change in HF signs and symptoms, requiring urgent medical therapies. Acute
      heart failure is estimated to be the most costly and the most frequent cause of admission to
      emergency wards. Emergency department (ED) is the primary setting where initial AHF
      management takes place. However, strong evidence for diagnostics and management of this grave
      condition is still lacking. Even less is known about the prevalence, diagnosis and management
      of acute right ventricular failure (RVF).

      A patient presenting to the ED with acute dyspnea has to undergo numerous procedures in order
      to differentiate the diagnosis between AHF, chronic obstructive pulmonary disease, pneumonia,
      pulmonary embolism and other etiologies. Moreover, the majority of HF patients suffer from
      comorbidities that make the diagnostic process even more challenging. Due to numerous exams
      and tests, the initial management of these patients may be delayed, resulting in an extended
      hospital length of stay, increased rate of complications and death. The clinical, hemodynamic
      and neurohormonal features of heart failure are diﬀerent in specific patient populations and
      depend on age, sex, race, left ventricular ejection fraction and co-existent right
      ventricular (RV) dysfunction as well as many other factors.

      Cardiac biomarkers are easily reproducible and objective laboratory tests that could help to
      improve early AHF diagnosis and risk stratification. However, reported data suggest varying
      prognostic and diagnostic values of natriuretic peptides, such as N-type natriuretic peptide
      (BNP), N-terminal pro B-type natriuretic peptide (NT-proBNP), MR pro-atrial natriuretic
      peptide (MR-proANP), as well as regional differences of these markers. Specific biomarkers of
      RVF have not yet been described, thus a search of novel serologic markers that could rapidly
      and reliably help diagnose acute RVF is a very important scientific task in cardiology.
      Furthermore, the knowledge on the incidence of RVF syndrome as well as the diagnostic and
      prognostic values of ultrasound RV structural and functional parameters is scarce. During
      this study the RV-focused ultrasound examination will be performed in the early
      hospitalization period, and blood samples will be taken and frozen at the same time. Up to 15
      novel cardiac, vascular, renal impairment and inflammation biomarkers in plasma samples
      during acute phase of RVF will be investigated during the study in France, INSERM laboratory.
      The study will be unique as it will aggregate large scale observational and biomarkers
      database of AHF patients in Lithuania together with innovative ultrasound parameters of RV
      failure (quantitative parameters of RV systolic function and deformation).

      The aim of this project is to find the specific novel biomarkers of acute heart failure
      (AHF), to evaluate their diagnostic and prognostic role in association with echocardiographic
      parameters of AHF.

      The primary endpoint is 1-year all-cause mortality and rehospitalization.

      Secondary endpoints are:

        1. in-hospital all-cause mortality

        2. post-discharge 1 and 3 months all-cause mortality and rehospitalization

        3. post-discharge 1 and 3 months cardiovascular mortality and rehospitalization

        4. one-year cardiovascular mortality and rehospitalization.

      Objectives of this project are:

        1. To create a database of patients hospitalized due to acute heart failure in Lithuania,
           integrated to GREAT (Global Research on Acute Conditions Team) network database;

        2. To compare the diagnostic and prognostic value of novel cardiac, vascular, renal
           insuﬃciency and inflammation biomarkers in the Lithuanian patient cohort to other
           countries in the GREAT network;

        3. To determine the demographic, clinical and treatment characteristics as well as short
           and long term outcome of patients hospitalized due to AHF in Lithuania and other GREAT
           network countries;

        4. To evaluate the epidemiology of RVF together with clinical features and outcome of
           patients in a cohort of Lithuanian acute heart failure (HF) patients;

        5. To estimate a correlation between ultrasound parameters of RV structure and function and
           novel cardiac, vascular, renal and inflammation biomarkers in acute period of HF;

        6. To identify novel ultrasound parameters of RV structure and function parameters and
           biomarkers predicting a risk of 1 year mortality after hospitalization;

        7. To create an algorithm of RV failure diagnostics and risk stratification based on the
           diagnostic and prognostic value of detected echocardiographic parameters and biomarkers.

      Observational studies and recent meta-analyses indicate that in acute conditions RVF may be
      as frequent as let ventricular failure (LVF) and is associated with markedly poor prognosis.
      Largely empiric knowledge in emergency medicine suggests that right and left ventricular
      failure requires diﬀerent therapeutic approaches, including disparate principles of
      intravenous treatment, due to distinct hemodynamic impairment. The outcome of RVF is largely
      dependent on the underlying cause, resulting in either an acute or chronic presentation.

      Novel biomarkers can help identify the underlying conditions in AHF. These include myocardial
      injury markers such as copeptine, proenkephalin, high sensitivity troponin T, troponin I,
      brain natriuretic peptide (BNP), N-terminal-proBNP; renal and hepatic involvement markers
      such as adrenomedullin, neutrophil gelatinase-associated lipocalin (NGAL), L-type fatty acid
      binding protein (L-FABP), galectin-3, soluble ST2, cystatin C; inflammatory markers such as
      C-reactive protein, interleukine 6, procalcitonin. These markers could help evaluate
      end-organ involvement, as well as the extent of myocardial remodeling, and in return provide
      state-of-the-art tailored patient care. Specific biomarkers of RV involvement or dysfunction
      have not yet been described, therefore identification of such biomarkers would allow to
      accelerate the diagnosis of RVF and initiate specific treatment.

      Echocardiography is a potent and accessible technique for the diagnosis of AHF in an acute
      setting. Echocardiography also provides information about the mechanisms of AHF as well as
      alternative causes of dyspnea. Echocardiographic parameters of RV structure and function are
      of particular interest since not much data is available on acute RVF. Quantitative parameters
      of RV systolic and diastolic function, RV wall deformation or notional hemodynamic parameters
      could potentially be useful for diagnosis and selection of urgent treatment tactics. In the
      current literature there are no publications about the diagnostic and prognostic value of RV
      parameters, especially about novel echocardiographic parameters (strain rate, speckle
      tracking), in the early phase of exacerbated heart failure.

      Global Research on Acute Conditions Teal (GREAT) Association is an international network
      among experts operating in the management of acute clinical conditions in the field of
      emergency medicine and doing research through the concept of translational medicine. This
      network integrates research inputs from basic sciences and interventional epidemiology to
      optimize both patient care and preventive measures. Moreover, one of the main objectives of
      the GREAT association is to standardize the clinical and organizational system approach in
      acute conditions disease management all over the world, with the concept of globalization
      medicine. Up to this day there has not been any large multicenter observational and
      biomarkers studies in Lithuania in the field of AHF. Our study creates a unique opportunity
      to join the worldwide GREAT network and its patient database, that could potentially contain
      up to 50 000 patients.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>1-year all-cause mortality and rehospitalization</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital all-cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-discharge all-cause mortality and rehospitalization</measure>
    <time_frame>1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-discharge cardiovascular mortality and rehospitalization</measure>
    <time_frame>1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year cardiovascular mortality and rehospitalization</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Prognostic role of circulating biomarkers</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prognostic role of echocardiographic parameters</measure>
    <time_frame>1 year</time_frame>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>Acute heart failure patients</arm_group_label>
    <description>Adult patients (18 years and older) who are admitted to the emergency department (Vilnius University Hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences Kauno Klinikos) due to acute dyspnea and have an adjudicated diagnosis of acute heart failure. Blood sampling and echocardiography examination will be performed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <description>Patients who are admitted to the emergency departments of participating centers due to acute dyspnea with an adjudicated diagnosis other than heart failure (pulmonary causes of dyspnea such as pulmonary embolism, acute infections, cancer and other reasons). Blood sampling and echocardiography examination will be performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sampling</intervention_name>
    <description>Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.</description>
    <arm_group_label>Acute heart failure patients</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Echocardiography exam</intervention_name>
    <description>A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.</description>
    <arm_group_label>Acute heart failure patients</arm_group_label>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients (18 years and older) who present to the hospital (Vilnius University
        hospital Santariškių Klinikos and Hospital of Lithuanian University of Health Sciences
        Kauno Klinikos) due to acute dyspnea. Besides acute heart failure, patients with pulmonary
        causes of dyspnea as well as pulmonary embolism, acute infections, cancer and other reasons
        are enrolled. Patients admitted to the ward as well as and discharged home from the
        emergency department are enrolled.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  presentation to hospital with acute dyspnea.

        Exclusion Criteria:

          -  refusal to give informed consent; acute coronary syndromes.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jelena Celutkiene, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Vilnius University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ausra Kavoliuniene, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lithuanian University of Health Sciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alexandre Mebazaa, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>INSERM, BIOmarkers in CArdioNeuroVAScular diseases</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jelena Celutkiene, Professor</last_name>
    <phone>+370 616 00 180</phone>
    <email>jelena.celutkiene@santa.lt</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ausra Kavoliuniene, Professor</last_name>
    <phone>+370 610 56 913</phone>
    <email>ausra.kavoliuniene@kaunoklinikos.lt</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Inserm U942</name>
      <address>
        <city>Paris</city>
        <state>Ile de France</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lithuanian University of Health Sciences</name>
      <address>
        <city>Kaunas</city>
        <zip>50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ausra Kavoliuniene, professor</last_name>
      <phone>+37061056913</phone>
      <email>ausra.kavoliuniene@kaunoklinikos.lt</email>
    </contact>
    <contact_backup>
      <last_name>Diana Zaliaduonyte-Peksiene, MD, PhD</last_name>
      <phone>+37061150776</phone>
      <email>diana.peksiene@kaunoklinikos.lt</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Zaliaduonyte-Peksiene, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jolanta Laukaitiene, assoc. prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ruta Jurgaitiene, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kestutis Stasaitis, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ausra Kavoliuniene, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vilnius University</name>
      <address>
        <city>Vilnius</city>
        <zip>08406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Celutkiene, Professor</last_name>
      <phone>+37061600180</phone>
      <email>jelena.celutkiene@santa.lt</email>
    </contact>
    <contact_backup>
      <last_name>Mindaugas Balciunas, MD, PhD</last_name>
      <email>Mindaugas.Balciunas@santa.lt</email>
    </contact_backup>
    <investigator>
      <last_name>Mindaugas Balciunas, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loreta Bagdonaite, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Diana Zakarkaite, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jelena Celutkiene, professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Kablucko, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vytautas Juknevicius, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Lithuania</country>
  </location_countries>
  <reference>
    <citation>Kaur M, Sprague S, Ignacy T, Thoma A, Bhandari M, Farrokhyar F. How to optimize participant retention and complete follow-up in surgical research. Can J Surg. 2014 Dec;57(6):420-7.</citation>
    <PMID>25421086</PMID>
  </reference>
  <reference>
    <citation>Lasagna L. Problems in publication of clinical trial methodology. Clin Pharmacol Ther. 1979 May;25(5 Pt 2):751-3.</citation>
    <PMID>373967</PMID>
  </reference>
  <reference>
    <citation>Gullen WH, Bearman JE, Calvert JC, Loewenson RB. Medical statistics: unscrambling the clinical research egg. Patient Care. 1978 May 30;12(10):120-2, 127, 130-2 passim.</citation>
    <PMID>10236742</PMID>
  </reference>
  <reference>
    <citation>Julious SA, Owen RJ. Sample size calculations for clinical studies allowing for uncertainty about the variance. Pharm Stat. 2006 Jan-Mar;5(1):29-37.</citation>
    <PMID>17080926</PMID>
  </reference>
  <reference>
    <citation>Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016 Aug;18(8):891-975. doi: 10.1002/ejhf.592. Epub 2016 May 20.</citation>
    <PMID>27207191</PMID>
  </reference>
  <reference>
    <citation>Zannad F, Mebazaa A, Juillière Y, Cohen-Solal A, Guize L, Alla F, Rougé P, Blin P, Barlet MH, Paolozzi L, Vincent C, Desnos M, Samii K; EFICA Investigators. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail. 2006 Nov;8(7):697-705. Epub 2006 Mar 3.</citation>
    <PMID>16516552</PMID>
  </reference>
  <reference>
    <citation>Maisel AS, Peacock WF, McMullin N, Jessie R, Fonarow GC, Wynne J, Mills RM. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol. 2008 Aug 12;52(7):534-40. doi: 10.1016/j.jacc.2008.05.010.</citation>
    <PMID>18687247</PMID>
  </reference>
  <reference>
    <citation>Emerman CL. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency department. Rev Cardiovasc Med. 2003;4 Suppl 7:S13-20. Review.</citation>
    <PMID>14668696</PMID>
  </reference>
  <reference>
    <citation>Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail. 2009 Nov-Dec;15(6):256-64. doi: 10.1111/j.1751-7133.2009.00112.x.</citation>
    <PMID>19925503</PMID>
  </reference>
  <reference>
    <citation>Masip J, Roque M, Sánchez B, Fernández R, Subirana M, Expósito JA. Noninvasive ventilation in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA. 2005 Dec 28;294(24):3124-30. Review.</citation>
    <PMID>16380593</PMID>
  </reference>
  <reference>
    <citation>Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P, Omland T, Storrow AB, Krishnaswamy P, Abraham WT, Clopton P, Steg G, Aumont MC, Westheim A, Knudsen CW, Perez A, Kamin R, Kazanegra R, Herrmann HC, McCullough PA; Breathing Not Properly Multinational Study Investigators. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study. J Am Coll Cardiol. 2003 Jun 4;41(11):2010-7.</citation>
    <PMID>12798574</PMID>
  </reference>
  <reference>
    <citation>Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol. 2005 Apr 15;95(8):948-54.</citation>
    <PMID>15820160</PMID>
  </reference>
  <reference>
    <citation>Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH; ADHERE Investigators. Cardiac troponin and outcome in acute heart failure. N Engl J Med. 2008 May 15;358(20):2117-26. doi: 10.1056/NEJMoa0706824.</citation>
    <PMID>18480204</PMID>
  </reference>
  <reference>
    <citation>Logeart D, Isnard R, Resche-Rigon M, Seronde MF, de Groote P, Jondeau G, Galinier M, Mulak G, Donal E, Delahaye F, Juilliere Y, Damy T, Jourdain P, Bauer F, Eicher JC, Neuder Y, Trochu JN; Heart Failure of the French Society of Cardiology. Current aspects of the spectrum of acute heart failure syndromes in a real-life setting: the OFICA study. Eur J Heart Fail. 2013 Apr;15(4):465-76. doi: 10.1093/eurjhf/hfs189. Epub 2012 Nov 27.</citation>
    <PMID>23186936</PMID>
  </reference>
  <reference>
    <citation>Chioncel O, Ambrosy AP, Bubenek S, Filipescu D, Vinereanu D, Petris A, Christodorescu R, Macarie C, Gheorghiade M, Collins SP; Romanian Acute Heart Failure Syndromes study investigators. Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry. J Cardiovasc Med (Hagerstown). 2016 Feb;17(2):92-104. doi: 10.2459/JCM.0000000000000192.</citation>
    <PMID>25252041</PMID>
  </reference>
  <reference>
    <citation>Bĕlohlávek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013 Spring;18(2):129-38.</citation>
    <PMID>23940438</PMID>
  </reference>
  <reference>
    <citation>Kinch JW, Ryan TJ. Right ventricular infarction. N Engl J Med. 1994 Apr 28;330(17):1211-7. Review.</citation>
    <PMID>8139631</PMID>
  </reference>
  <reference>
    <citation>Naeije R, Brimioulle S, Dewachter L. Biomechanics of the right ventricle in health and disease (2013 Grover Conference series). Pulm Circ. 2014 Sep;4(3):395-406. doi: 10.1086/677354. Review.</citation>
    <PMID>25621153</PMID>
  </reference>
  <reference>
    <citation>Berlin DA, Bakker J. Understanding venous return. Intensive Care Med. 2014 Oct;40(10):1564-6. doi: 10.1007/s00134-014-3379-4. Epub 2014 Jun 26. Review.</citation>
    <PMID>24966066</PMID>
  </reference>
  <reference>
    <citation>Haddad F, Couture P, Tousignant C, Denault AY. The right ventricle in cardiac surgery, a perioperative perspective: I. Anatomy, physiology, and assessment. Anesth Analg. 2009 Feb;108(2):407-21. doi: 10.1213/ane.0b013e31818f8623. Review.</citation>
    <PMID>19151264</PMID>
  </reference>
  <reference>
    <citation>Markel TA, Wairiuko GM, Lahm T, Crisostomo PR, Wang M, Herring CM, Meldrum DR. The right heart and its distinct mechanisms of development, function, and failure. J Surg Res. 2008 May 15;146(2):304-13. Epub 2007 Nov 26. Review.</citation>
    <PMID>18036544</PMID>
  </reference>
  <reference>
    <citation>Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WH. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009 Feb 17;53(7):589-96. doi: 10.1016/j.jacc.2008.05.068.</citation>
    <PMID>19215833</PMID>
  </reference>
  <reference>
    <citation>Lankeit M, Jiménez D, Kostrubiec M, Dellas C, Hasenfuss G, Pruszczyk P, Konstantinides S. Predictive value of the high-sensitivity troponin T assay and the simplified Pulmonary Embolism Severity Index in hemodynamically stable patients with acute pulmonary embolism: a prospective validation study. Circulation. 2011 Dec 13;124(24):2716-24. doi: 10.1161/CIRCULATIONAHA.111.051177. Epub 2011 Nov 14.</citation>
    <PMID>22082681</PMID>
  </reference>
  <reference>
    <citation>Sztrymf B, Souza R, Bertoletti L, Jaïs X, Sitbon O, Price LC, Simonneau G, Humbert M. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur Respir J. 2010 Jun;35(6):1286-93. doi: 10.1183/09031936.00070209. Epub 2009 Nov 6.</citation>
    <PMID>19897557</PMID>
  </reference>
  <reference>
    <citation>Naito A, Tanabe N, Jujo T, Shigeta A, Sugiura T, Sakao S, Ishida K, Tatsumi K. Pentraxin3 in chronic thromboembolic pulmonary hypertension: a new biomarker for screening from remitted pulmonary thromboembolism. PLoS One. 2014 Nov 20;9(11):e113086. doi: 10.1371/journal.pone.0113086. eCollection 2014.</citation>
    <PMID>25412085</PMID>
  </reference>
  <reference>
    <citation>Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, Solomon SD, Louie EK, Schiller NB. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr. 2010 Jul;23(7):685-713; quiz 786-8. doi: 10.1016/j.echo.2010.05.010.</citation>
    <PMID>20620859</PMID>
  </reference>
  <reference>
    <citation>Ghignone M, Girling L, Prewitt RM. Volume expansion versus norepinephrine in treatment of a low cardiac output complicating an acute increase in right ventricular afterload in dogs. Anesthesiology. 1984 Feb;60(2):132-5.</citation>
    <PMID>6198941</PMID>
  </reference>
  <reference>
    <citation>Zannad F, Adamopoulos C, Mebazaa A, Gheorghiade M. The challenge of acute decompensated heart failure. Heart Fail Rev. 2006 Jun;11(2):135-9. Review.</citation>
    <PMID>16937032</PMID>
  </reference>
  <reference>
    <citation>Ng TM, Singh AK, Dasta JF, Feldman D, Mebazaa A. Contemporary issues in the pharmacologic management of acute heart failure. Crit Care Clin. 2006 Apr;22(2):199-219, v. Review.</citation>
    <PMID>16677996</PMID>
  </reference>
  <reference>
    <citation>De Luca L, Fonarow GC, Adams KF Jr, Mebazaa A, Tavazzi L, Swedberg K, Gheorghiade M. Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy. Heart Fail Rev. 2007 Jun;12(2):97-104. Review.</citation>
    <PMID>17487581</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M; SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007 May 2;297(17):1883-91.</citation>
    <PMID>17473298</PMID>
  </reference>
  <reference>
    <citation>Adamopoulos C, Zannad F, Fay R, Mebazaa A, Cohen-Solal A, Guize L, Juillière Y, Alla F. Ejection fraction and blood pressure are important and interactive predictors of 4-week mortality in severe acute heart failure. Eur J Heart Fail. 2007 Sep;9(9):935-41. Epub 2007 Jul 12.</citation>
    <PMID>17627880</PMID>
  </reference>
  <reference>
    <citation>Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, Peacock WF, Fonarow GC, Aldeen AZ, Kirk JD, Storrow AB, Tavares M, Mebazaa A, Roland E, Massie BM, Maisel AS, Komajda M, Filippatos G, Gheorghiade M; Acute Heart Failure Syndromes International Working Group. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J. 2008 Mar;29(6):816-24. doi: 10.1093/eurheartj/ehn048. Epub 2008 Mar 1.</citation>
    <PMID>18310669</PMID>
  </reference>
  <reference>
    <citation>Huvelle E, Fay R, Alla F, Cohen Solal A, Mebazaa A, Zannad F. Left bundle branch block and mortality in patients with acute heart failure syndrome: a substudy of the EFICA cohort. Eur J Heart Fail. 2010 Feb;12(2):156-63. doi: 10.1093/eurjhf/hfp180. Epub 2009 Dec 21.</citation>
    <PMID>20028696</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Pang PS, Tavares M, Collins SP, Storrow AB, Laribi S, Andre S, Mark Courtney D, Hasa J, Spinar J, Masip J, Frank Peacock W, Sliwa K, Gayat E, Filippatos G, Cleland JG, Gheorghiade M. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J. 2010 Apr;31(7):832-41. doi: 10.1093/eurheartj/ehp458. Epub 2009 Nov 11.</citation>
    <PMID>19906690</PMID>
  </reference>
  <reference>
    <citation>Böhm M, Link A, Cai D, Nieminen MS, Filippatos GS, Salem R, Cohen Solal A, Huang B, Padley RJ, Kivikko M, Mebazaa A. Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial. Crit Care Med. 2011 May;39(5):940-4. doi: 10.1097/CCM.0b013e31820a91ed.</citation>
    <PMID>21283007</PMID>
  </reference>
  <reference>
    <citation>Laribi S, Aouba A, Nikolaou M, Lassus J, Cohen-Solal A, Plaisance P, Pavillon G, Jois P, Fonarow GC, Jougla E, Mebazaa A; GREAT network. Trends in death attributed to heart failure over the past two decades in Europe. Eur J Heart Fail. 2012 Mar;14(3):234-9. doi: 10.1093/eurjhf/hfr182. Epub 2012 Jan 10.</citation>
    <PMID>22237388</PMID>
  </reference>
  <reference>
    <citation>Parissis JT, Rafouli-Stergiou P, Mebazaa A, Ikonomidis I, Bistola V, Nikolaou M, Meas T, Delgado J, Vilas-Boas F, Paraskevaidis I, Anastasiou-Nana M, Follath F. Acute heart failure in patients with diabetes mellitus: clinical characteristics and predictors of in-hospital mortality. Int J Cardiol. 2012 May 17;157(1):108-13. doi: 10.1016/j.ijcard.2011.11.098. Epub 2011 Dec 15.</citation>
    <PMID>22178056</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Vanpoucke G, Thomas G, Verleysen K, Cohen-Solal A, Vanderheyden M, Bartunek J, Mueller C, Launay JM, Van Landuyt N, D'Hondt F, Verschuere E, Vanhaute C, Tuytten R, Vanneste L, De Cremer K, Wuyts J, Davies H, Moerman P, Logeart D, Collet C, Lortat-Jacob B, Tavares M, Laroy W, Januzzi JL, Samuel JL, Kas K. Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J. 2012 Sep;33(18):2317-24. doi: 10.1093/eurheartj/ehs162. Epub 2012 Jun 24.</citation>
    <PMID>22733835</PMID>
  </reference>
  <reference>
    <citation>Breidthardt T, Vanpoucke G, Potocki M, Mosimann T, Ziller R, Thomas G, Laroy W, Moerman P, Socrates T, Drexler B, Mebazaa A, Kas K, Mueller C. The novel marker LTBP2 predicts all-cause and pulmonary death in patients with acute dyspnoea. Clin Sci (Lond). 2012 Nov;123(9):557-66. doi: 10.1042/CS20120058.</citation>
    <PMID>22587491</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye N, Boukef R, Collet C, Van den Berghe G, Cohen-Solal A, Januzzi JL Jr; GREAT Network. Association between elevated blood glucose and outcome in acute heart failure: results from an international observational cohort. J Am Coll Cardiol. 2013 Feb 26;61(8):820-9. doi: 10.1016/j.jacc.2012.11.054. Epub 2013 Jan 16.</citation>
    <PMID>23333145</PMID>
  </reference>
  <reference>
    <citation>Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebazaa A; GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013 Oct 3;168(3):2186-94. doi: 10.1016/j.ijcard.2013.01.228. Epub 2013 Mar 26.</citation>
    <PMID>23538053</PMID>
  </reference>
  <reference>
    <citation>Seronde MF, Gayat E, Logeart D, Lassus J, Laribi S, Boukef R, Sibellas F, Launay JM, Manivet P, Sadoune M, Nouira S, Solal AC, Mebazaa A; Great network. Comparison of the diagnostic and prognostic values of B-type and atrial-type natriuretic peptides in acute heart failure. Int J Cardiol. 2013 Oct 9;168(4):3404-11. doi: 10.1016/j.ijcard.2013.04.164. Epub 2013 May 14.</citation>
    <PMID>23684562</PMID>
  </reference>
  <reference>
    <citation>Shah R, Gayat E, Januzzi JL Jr, Sato N, Cohen-Solal A, diSomma S, Fairman E, Harjola VP, Ishihara S, Lassus J, Maggioni A, Metra M, Mueller C, Mueller T, Parenica J, Pascual-Figal D, Peacock WF, Spinar J, van Kimmenade R, Mebazaa A; GREAT (Global Research on Acute Conditions Team) Network. Body mass index and mortality in acutely decompensated heart failure across the world: a global obesity paradox. J Am Coll Cardiol. 2014 Mar 4;63(8):778-85. doi: 10.1016/j.jacc.2013.09.072. Epub 2013 Dec 4.</citation>
    <PMID>24315906</PMID>
  </reference>
  <reference>
    <citation>Cohen AT, Spiro TE, Spyropoulos AC, Desanctis YH, Homering M, Büller HR, Haskell L, Hu D, Hull R, Mebazaa A, Merli G, Schellong S, Tapson VF, Burton P; MAGELLAN Study Group. D-dimer as a predictor of venous thromboembolism in acutely ill, hospitalized patients: a subanalysis of the randomized controlled MAGELLAN trial. J Thromb Haemost. 2014 Apr;12(4):479-87. doi: 10.1111/jth.12515.</citation>
    <PMID>24460645</PMID>
  </reference>
  <reference>
    <citation>Pang PS, Collins SP, Sauser K, Andrei AC, Storrow AB, Hollander JE, Tavares M, Spinar J, Macarie C, Raev D, Nowak R, Gheorghiade M, Mebazaa A. Assessment of dyspnea early in acute heart failure: patient characteristics and response differences between likert and visual analog scales. Acad Emerg Med. 2014 Jun;21(6):659-66. doi: 10.1111/acem.12390.</citation>
    <PMID>25039550</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Spiro TE, Büller HR, Haskell L, Hu D, Hull R, Merli G, Schellong SW, Spyropoulos AC, Tapson VF, De Sanctis Y, Cohen AT. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation. 2014 Jul 29;130(5):410-8. doi: 10.1161/CIRCULATIONAHA.113.003126. Epub 2014 Jun 26.</citation>
    <PMID>24970782</PMID>
  </reference>
  <reference>
    <citation>Vodovar N, Séronde MF, Laribi S, Gayat E, Lassus J, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Ishihara S, Cohen Solal A, Januzzi JL Jr, Richards AM, Launay JM, Mebazaa A; GREAT Network. Post-translational modifications enhance NT-proBNP and BNP production in acute decompensated heart failure. Eur Heart J. 2014 Dec 21;35(48):3434-41. doi: 10.1093/eurheartj/ehu314. Epub 2014 Aug 24.</citation>
    <PMID>25157115</PMID>
  </reference>
  <reference>
    <citation>Cohen-Solal A, Laribi S, Ishihara S, Vergaro G, Baudet M, Logeart D, Mebazaa A, Gayat E, Vodovar N, Pascual-Figal DA, Seronde MF. Prognostic markers of acute decompensated heart failure: the emerging roles of cardiac biomarkers and prognostic scores. Arch Cardiovasc Dis. 2015 Jan;108(1):64-74. doi: 10.1016/j.acvd.2014.10.002. Epub 2014 Nov 4. Review.</citation>
    <PMID>25534886</PMID>
  </reference>
  <reference>
    <citation>Parissis JT, Andreoli C, Kadoglou N, Ikonomidis I, Farmakis D, Dimopoulou I, Iliodromitis E, Anastasiou-Nana M, Lainscak M, Ambrosio G, Mebazaa A, Filippatos G, Follath F. Differences in clinical characteristics, management and short-term outcome between acute heart failure patients chronic obstructive pulmonary disease and those without this co-morbidity. Clin Res Cardiol. 2014 Sep;103(9):733-41. doi: 10.1007/s00392-014-0708-0. Epub 2014 Apr 10.</citation>
    <PMID>24718849</PMID>
  </reference>
  <reference>
    <citation>Legrand M, Mebazaa A, Ronco C, Januzzi JL Jr. When cardiac failure, kidney dysfunction, and kidney injury intersect in acute conditions: the case of cardiorenal syndrome. Crit Care Med. 2014 Sep;42(9):2109-17. doi: 10.1097/CCM.0000000000000404. Review.</citation>
    <PMID>24810531</PMID>
  </reference>
  <reference>
    <citation>Kelly JP, Mentz RJ, Mebazaa A, Voors AA, Butler J, Roessig L, Fiuzat M, Zannad F, Pitt B, O'Connor CM, Lam CSP. Patient selection in heart failure with preserved ejection fraction clinical trials. J Am Coll Cardiol. 2015 Apr 28;65(16):1668-1682. doi: 10.1016/j.jacc.2015.03.043. Review.</citation>
    <PMID>25908073</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Yilmaz MB, Levy P, Ponikowski P, Peacock WF, Laribi S, Ristic AD, Lambrinou E, Masip J, Riley JP, McDonagh T, Mueller C, deFilippi C, Harjola VP, Thiele H, Piepoli MF, Metra M, Maggioni A, McMurray J, Dickstein K, Damman K, Seferovic PM, Ruschitzka F, Leite-Moreira AF, Bellou A, Anker SD, Filippatos G. Recommendations on pre-hospital &amp; early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine. Eur J Heart Fail. 2015 Jun;17(6):544-58. doi: 10.1002/ejhf.289. Epub 2015 May 21. Review.</citation>
    <PMID>25999021</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Longrois D, Metra M, Mueller C, Richards AM, Roessig L, Seronde MF, Sato N, Stockbridge NL, Gattis Stough W, Alonso A, Cody RJ, Cook Bruns N, Gheorghiade M, Holzmeister J, Laribi S, Zannad F. Agents with vasodilator properties in acute heart failure: how to design successful trials. Eur J Heart Fail. 2015 Jul;17(7):652-64. doi: 10.1002/ejhf.294. Epub 2015 Jun 4. Review.</citation>
    <PMID>26040488</PMID>
  </reference>
  <reference>
    <citation>Jaffe AS, Apple FS, Mebazaa A, Vodovar N. Unraveling N-terminal pro-B-type natriuretic peptide: another piece to a very complex puzzle in heart failure patients. Clin Chem. 2015 Aug;61(8):1016-8. doi: 10.1373/clinchem.2015.243626. Epub 2015 Jun 15.</citation>
    <PMID>26078443</PMID>
  </reference>
  <reference>
    <citation>Gayat E, Caillard A, Laribi S, Mueller C, Sadoune M, Seronde MF, Maisel A, Bartunek J, Vanderheyden M, Desutter J, Dendale P, Thomas G, Tavares M, Cohen-Solal A, Samuel JL, Mebazaa A. Soluble CD146, a new endothelial biomarker of acutely decompensated heart failure. Int J Cardiol. 2015 Nov 15;199:241-7. doi: 10.1016/j.ijcard.2015.07.039. Epub 2015 Jul 12.</citation>
    <PMID>26209827</PMID>
  </reference>
  <reference>
    <citation>Vodovar N, Séronde MF, Laribi S, Gayat E, Lassus J, Januzzi JL Jr, Boukef R, Nouira S, Manivet P, Samuel JL, Logeart D, Cohen-Solal A, Richards AM, Launay JM, Mebazaa A; GREAT Network. Elevated Plasma B-Type Natriuretic Peptide Concentrations Directly Inhibit Circulating Neprilysin Activity in Heart Failure. JACC Heart Fail. 2015 Aug;3(8):629-36. doi: 10.1016/j.jchf.2015.03.011.</citation>
    <PMID>26251090</PMID>
  </reference>
  <reference>
    <citation>Teixeira A, Parenica J, Park JJ, Ishihara S, AlHabib KF, Laribi S, Maggioni A, Miró Ò, Sato N, Kajimoto K, Cohen-Solal A, Fairman E, Lassus J, Mueller C, Peacock WF, Januzzi JL Jr, Choi DJ, Plaisance P, Spinar J, Mebazaa A, Gayat E; GREAT (Global Research on Acute Conditions Team) Network. Clinical presentation and outcome by age categories in acute heart failure: results from an international observational cohort. Eur J Heart Fail. 2015 Nov;17(11):1114-23. doi: 10.1002/ejhf.330. Epub 2015 Sep 30.</citation>
    <PMID>26419908</PMID>
  </reference>
  <reference>
    <citation>Spinar J, Jarkovsky J, Spinarova L, Mebazaa A, Gayat E, Vitovec J, Linhart A, Widimsky P, Miklik R, Zeman K, Belohlavek J, Malek F, Felsoci M, Kettner J, Ostadal P, Cihalik C, Vaclavik J, Taborsky M, Dusek L, Littnerova S, Parenica J. AHEAD score--Long-term risk classification in acute heart failure. Int J Cardiol. 2016 Jan 1;202:21-6. doi: 10.1016/j.ijcard.2015.08.187. Epub 2015 Aug 28.</citation>
    <PMID>26386914</PMID>
  </reference>
  <reference>
    <citation>Mebazaa A, Tolppanen H, Mueller C, Lassus J, DiSomma S, Baksyte G, Cecconi M, Choi DJ, Cohen Solal A, Christ M, Masip J, Arrigo M, Nouira S, Ojji D, Peacock F, Richards M, Sato N, Sliwa K, Spinar J, Thiele H, Yilmaz MB, Januzzi J. Acute heart failure and cardiogenic shock: a multidisciplinary practical guidance. Intensive Care Med. 2016 Feb;42(2):147-63. doi: 10.1007/s00134-015-4041-5. Epub 2015 Sep 14. Review.</citation>
    <PMID>26370690</PMID>
  </reference>
  <reference>
    <citation>Parissis J, Farmakis D, Kadoglou N, Ikonomidis I, Fountoulaki E, Hatziagelaki E, Deftereos S, Follath F, Mebazaa A, Lekakis J, Filippatos G. Body mass index in acute heart failure: association with clinical profile, therapeutic management and in-hospital outcome. Eur J Heart Fail. 2016 Mar;18(3):298-305. doi: 10.1002/ejhf.489. Epub 2016 Jan 28.</citation>
    <PMID>26817848</PMID>
  </reference>
  <reference>
    <citation>Harjola VP, Mebazaa A, Čelutkienė J, Bettex D, Bueno H, Chioncel O, Crespo-Leiro MG, Falk V, Filippatos G, Gibbs S, Leite-Moreira A, Lassus J, Masip J, Mueller C, Mullens W, Naeije R, Nordegraaf AV, Parissis J, Riley JP, Ristic A, Rosano G, Rudiger A, Ruschitzka F, Seferovic P, Sztrymf B, Vieillard-Baron A, Yilmaz MB, Konstantinides S. Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. Eur J Heart Fail. 2016 Mar;18(3):226-41. doi: 10.1002/ejhf.478. Review.</citation>
    <PMID>26995592</PMID>
  </reference>
  <reference>
    <citation>Van Aelst LN, Čelutkienė J, Mebazaa A. Advanced heart failure: look right to prognosticate right! Eur J Heart Fail. 2016 May;18(5):573-5. doi: 10.1002/ejhf.533.</citation>
    <PMID>27135771</PMID>
  </reference>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2017</study_first_submitted>
  <study_first_submitted_qc>February 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2017</study_first_posted>
  <last_update_submitted>February 7, 2017</last_update_submitted>
  <last_update_submitted_qc>February 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vilnius University</investigator_affiliation>
    <investigator_full_name>Jelena Čelutkienė</investigator_full_name>
    <investigator_title>Senior Researcher and Professor in Clinic of Cardiac and Vascular Diseases, Centre of Cardiology and Angiology, Vilnius University; Senior cardiologist in Unit of Stress testing, Vilnius University hospital Santariškių Klinikos</investigator_title>
  </responsible_party>
  <keyword>acute heart failure</keyword>
  <keyword>right ventricular failure</keyword>
  <keyword>cardiac biomarkers</keyword>
  <keyword>echocardiography</keyword>
  <keyword>diagnosis</keyword>
  <keyword>prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Dyspnea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data will be made available to other researchers via GREAT (Global REsearch on Acute Conditions Team) database</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

